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Abstract 
Background: To examine the feasibility of implementing clinician-supported inpatient self-managed insulin to aid in 
the planning of a randomized clinical trial.
Results: We conducted a proof-of-concept interventional study of inpatients with diabetes mellitus who had hos-
pital orders for basal-bolus or sliding scale insulin. Patients meeting inclusion criteria were offered the opportunity to 
manage their own basal-bolus insulin with support from a diabetes nurse practitioner. Over a three-month screen-
ing period, we conducted 361 screens in 336 patients, only eleven of whom met all inclusion criteria. None of these 
eleven eligible patients elected to enroll. The most common reason for refusal was lack of interest in self-managing 
insulin while acutely ill (36 %).
Discussion: Future studies of patient-managed in-hospital insulin should consider enrolling less acutely ill patients 
with longer anticipated lengths of stay.
Trials registration: NCT02144441
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Background
Many patients with diabetes are adept at managing their 
home insulin regimen. When such patients become hos-
pitalized in the U.S., however, their insulin is managed 
by clinical staff who may not always use best practices 
to prescribe, administer, and monitor insulin. The poor 
quality of in-hospital insulin management [1] is docu-
mented by figures showing that hypoglycemia and hyper-
glycemia occur during 5.7 and 32  % of non-intensive 
care unit patient-days, respectively [2]. Patient-directed 
care is gaining acceptance in many areas of medicine, 
including diabetes care. [3] The American Diabetes 
Association states that “[d]iabetes self-management in 
the hospital may be appropriate for competent youth 
and adult patients” [4]. Moreover, with the high rates of 
adverse effects and the potential for prolonged length 
of stay due to ineffective insulin management by staff, if 
patient-managed insulin could prove to be more effec-
tive, it might reduce the cost of hospital care for diabe-
tes patients [5]. While patient management of in-hospital 
insulin is widespread in the UK, [5] few if any U.S. hos-
pitals allow patients to manage their own non-pump 
insulin, and no randomized clinical trials (RCTs) have 
evaluated this approach.
We therefore began planning a RCT to examine the 
safety and effectiveness of patient-managed in-hospital 
insulin versus hospital-managed insulin. To assess the 
feasibility of such a trial, we performed a proof-of-con-
cept pilot trial to answer the following questions: (1) 
What proportion of hospital inpatients receiving subcu-
taneous insulin meet inclusion criteria? (2) What propor-
tion of eligible patients are willing to participate? and (3) 
What proportion of subjects are able to continue insulin 
self-management throughout their hospital stay?
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Results
Methods
We designed a pilot trial with an intervention group but 
no control group. The study was conducted from July 
to November 2014 at the Hospital of the University of 
Pennsylvania. Enrollment was originally planned to be 
open for 6 months, but due low enrollment, was termi-
nated after 3 months. We originally started recruiting on 
a single medical unit, but because of a low enrollment 
expanded to two additional medical units and one surgi-
cal unit.
The intervention was to allow eligible inpatients to 
manage their own basal-bolus insulin regimen with sup-
port from diabetes nurse practitioners (DNPs). Written 
informed consent would have been obtained from all 
subjects. Physicians would order insulin glargine (Lan-
tus) vials and insulin aspart (NovoLog) flexpens without 
specifying doses. Subjects would have medication lock-
boxes placed at their bedside containing glargine vials, 
aspart pens, dextrose gel, a glucometer, and other neces-
sary blood glucose management supplies. A DNP would 
meet daily with each subject to develop and monitor 
their basal-bolus regimens. Subjects would be permitted 
to perform their own finger-stick blood glucose meas-
urements, administer their own insulin, and document 
glucometer readings and insulin doses on bedside flow 
sheets that would be reviewed by clinical staff and incor-
porated into the electronic medical record.
Inclusion criteria were: (1) admission or transfer to 
a participating floor in the 3 days prior to screening (to 
accommodate the lack of screening on weekends); (2) age 
≥18 years; (3) diagnosis of type-1 or 2 diabetes mellitus; 
(4) a home basal-bolus insulin regimen administered via 
subcutaneous injection rather than pump; (5) willing-
ness to use specified basal-bolus insulins (aspart pen and 
glargine vial); (6) most recent glycosylated hemoglobin of 
<7.5 % (<58 mmol/mol) measured in the 180 days prior 
to the current hospitalization; (7) active order for basal-
bolus or sliding scale insulin; (8) willingness to document 
self-measured blood glucose results, self-administered 
insulin doses, food intake, and physical activity; and (9) 
approval from the clinical team. Exclusion criteria were: 
(1) order for an insulin infusion or pump; (2) inability to 
perform physical activities necessary for the study; (3) 
primary reason for current admission was related to glu-
cose control or a medical condition that would impair the 
patient’s ability to manage insulin; (4) current order for 
a newly-prescribed corticosteroid or increased dose of a 
previously-prescribed corticosteroid; (5) enteral or par-
enteral nutrition; (6) expected length of stay <2 days; (7) 
risk for self-harm; (8) pregnancy; (9) inability to under-
stand, speak, or read English; (10) do-not-resuscitate sta-
tus; and (11) prior enrollment in this trial. Hereafter we 
will refer to inclusion and exclusion criteria as inclusion 
criteria. The primary criterion used to identify poten-
tial subjects was an inpatient order for basal-bolus or 
sliding-scale insulin on one of the units used for recruit-
ment. This criterion was utilized for subject identification 
as it was expected to be consistent and accurate within 
the medical record. The identified subjects were then 
screened for all other criteria.
The research questions, design, outcome measures, 
and the analytic plan were developed based on numer-
ous face-to-face meetings, telephone calls, and vide-
oconferences with patients with diabetes and with 
nonprofessional diabetes caregivers, as well as with 
nurses, physicians, pharmacists, the head of the clini-
cal lab, the Chief Medical Information Officer and other 
clinical and administrative personnel. Further, we gath-
ered critical insight from thought-leaders within a patient 
advocacy group, a community group, and professional 
associations. Then, in preparation for this pilot trial, we 
performed a retrospective chart review using hospi-
tal information systems. From this, we ascertained that 
18 % of patients admitted to our hospital have diabetes, 
and that 85  % of these patients receive subcutaneous 
insulin while hospitalized (the remainder receive insulin 
via intravenous infusion). We also ascertained that our 
population with diabetes has an average length of stay 
of 6.8 days. We further reviewed the electronic medical 
records of two random samples of insulin-treated inpa-
tients (NTotal  =  40) and ascertained that 20  % of these 
patients would meet inclusion criteria. And finally, we 
prospectively approached a convenience sample (N = 10) 
of inpatients meeting inclusion criteria to assess their 
willingness to participate in such a study. Nine out of 
the 10 (90 %) patients indicated without hesitation they 
would enroll, while the tenth patient could not decide 
immediately.
The measured outcomes were feasibility metrics 
including the number of patients screened, the number 
of patients deemed eligible, the number of enrolled sub-
jects, the proportion of subjects completing the inter-
vention, and subjects’ satisfaction with their inpatient 
diabetes care. The study was approved by the University 
of Pennsylvania’s Institutional Review Board and regis-
tered on ClinicalTrials.gov (NCT02144441).
Results
Operationalizing intervention procedures took approxi-
mately 18  months, which was longer than expected. 
This included obtaining approval from relevant clini-
cal departments, hospital committees, and hospital 
leadership.
During the 3  months of the study, we performed 361 
screenings in 336 patients with orders for basal-bolus 
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or sliding-scale insulin. Repeat screening occurred for 
patients with multiple admissions. Only 15 screens (4 %) 
appeared eligible based on chart review. Four of these 
15 screens (27  %) were interested in participating but 
did not meet the inclusion criteria assessed in person. 
The remaining eleven (73 %) did not wish to enroll. We 
determined that eight of the eleven subjects (73 %) who 
did not wish to enroll met all inclusion criteria, while 
the remaining three (27  %) would have required addi-
tional in-person screening to definitively determine eli-
gibility (Fig.  1). The most common reason for declining 
participation (cited by four of eleven declining patients 
[36 %]), was lack of interest in being responsible for man-
aging their own insulin therapy given their acute illness.
Discussion
We hypothesized that allowing eligible hospital inpa-
tients to manage their own insulin could improve the 
patient-centeredness of care and improve clinical out-
comes. We therefore performed a proof-of-concept pilot 
trial as a precursor to a RCT. Unexpectedly, in contrast to 
the results of a retrospective chart review and anecdotal 
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Fig. 1 Reasons for non-enrollment
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evidence obtained from multiple patient and professional 
sources, we found that very few patients met eligibil-
ity criteria, and none of the eight fully eligible subjects 
or the three potentially eligible subjects were interested 
in participating. We considered broadening our inclu-
sion criteria, including reducing the anticipated length 
of stay exclusion criterion from 48 to 24 h and increas-
ing the HbA1c threshold exclusion criterion from 7.5 to 
8 %, but decided not to because through interim analyses 
of screening failures, we found that these minor modi-
fications would likely have had little effect in increasing 
the number of eligible patients. While extensive con-
sideration was given to altering other criteria, we were 
concerned about the safety of self-managed insulin in 
patients not meeting original criteria within the param-
eters of our pilot design.
We hope that sharing these challenges can advance 
future research in patient-managed insulin. First, the 
most common reason for screen failure (65 %) was lack 
of experience managing basal-bolus insulin. This may be 
addressable in future studies by including patients whose 
home regimen is bolus- or basal-only insulin. Addition-
ally, it may be reasonable to limit inclusion to type-1 dia-
betes patients, who may be better trained in carbohydrate 
counting and therefore more likely to participate. The 
resulting reduction in the number of available patients 
could be accommodated by expanding to multiple cent-
ers. Second, given the short duration of typical hospital 
stays, the eligibility requirement for an expected length 
of stay of >48 h was responsible for 10 % of screening fail-
ures. However, this number probably underestimates the 
number of screen failures because we sometimes could 
not ascertain the expected length of stay for patients dis-
qualified for other reasons. The rationale for this crite-
rion was the time needed to educate the patient and the 
limited opportunity to observe a benefit over short stays. 
This may be addressable in future studies by including 
patient care units with longer average lengths of stay. And 
finally, among the eleven screens eligible for the study, 
the most common reason for refusal (36 %) was lack of 
interest in being responsible for their own glucose con-
trol during a period of acute illness. Future trials should 
consider recruiting on units where patients are typically 
less acutely ill or at skilled nursing facilities rather than 
hospitals.
Despite guidelines in the U.S. and internationally sup-
porting patient-managed in-hospital insulin [4, 5], there 
have been no RCTs assessing the efficacy and safety of 
this approach to care. We sought to assess the feasibility 
of an RCT by performing a proof-of-concept pilot trial, 
but found we were not able to enroll any subject using 
the selected inclusion criteria. The challenges we faced in 
enrolling patients may be useful to help inform research 
design and criteria to support future studies into in-hos-
pital patient-managed insulin. Based on our experiences, 
we would recommend future studies investigate patient 
self-managed insulin in the hospital by focusing recruit-
ment on patients with type 1 diabetes, on basal-bolus, 
basal-only or bolus-only regimens at home, who are 
admitted for non-acute illnesses, within units that typi-
cally require longer lengths of stay.
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